Biopsy Devices Market Size, Share & Trends Analysis Report By Product (Needle-based Biopsy Guns, Biopsy Guidance Systems, Biopsy Forceps, Biopsy Needles), By Region, Competitive Landscape, And Segment Forecasts, 2012 - 2020

Industry Outlook

The global biopsy devices market size was estimated at USD 1.0 billion in 2016. Growing prevalence of cancer worldwide and the presence of untapped opportunities in emerging economies, especially of Asia Pacific, along with improving healthcare infrastructure in these regions are among the key trends stoking market growth. Surging demand for effective diagnostic procedures for cancer is also expected to work in favor of the market.

Furthermore, spiraling demand for less invasive surgeries and disposable biopsy devices is anticipated to propel the market. Technologically advanced biopsy guidance systems, such as vacuum-assisted guns, are gaining popularity among patients and healthcare providers. The widening base of geriatric population and the introduction of cost-effective and advanced devices are anticipated to further boost the growth of the market.

According to statistics published by WHO, cancer has become one of the leading causes of death worldwide. The global incidence of cancer in 2012 was 14.1 million and it is awaited to rise by 70.0% over the next two decades.

The most common types of cancers that prove to be fatal for patients are colorectal cancer, breast cancer, lung cancer, liver cancer, and stomach cancer. The number of cases of cancer is likely to reach 23.6 million by 2030. Rising incidence of cancer is encouraging the development of more effective, safe, and advanced biopsy procedures.

Minimally invasive medical procedures offer several advantages, which has bolstered their popularity. Such procedures result in quicker recovery of patients and are less traumatic. Research results published by manufacturers suggest that minimally invasive surgeries are rapidly replacing invasive surgeries and providing higher patient satisfaction levels.

Besides this, aging is considered as one of the greatest risk factors for the development of cancer. Therefore, with the growing geriatric population worldwide, the number of biopsy devices and tests is projected to increase over the next few years. Globally, more than 70.0% of cancer deaths registered are of patients aged 65 and older. More than 50.0% of the cases diagnosed with cancer are of older adults.

As per a recent study by the Institute of Medicine, between 2010 and 2030, there was a 67.0% increase in the cases of cancer diagnosed in older patients as compared to an 11.0% increase in younger adults. The geriatric population is the highest in Asian countries, with Japan being on the forefront. Estimates suggest that more than 20.0% of the population in Japan is over the age of 65 years.

Growing cancer-related spending is triggering the need for effective diagnostic procedures. Government and healthcare regulatory bodies all across the world are constantly engaged in curbing high costs associated with the treatment of cancer. Primary and secondary healthcare centers in emerging nations are encouraging patients to undergo regular diagnostic examinations. The use of biopsy devices involves a relatively lesser number of hospital stays and therefore, is economically viable.

Product Insights

Needle-based biopsy guns held the leading share in the market in 2013. Surging demand for these guns for acquiring samples from soft tissues of internal organs such as breasts, kidneys, and lungs is poised to contribute to the growth of the overall market during the forecast horizon. Soaring need for rapid and gentle procurement of cell samples for biopsy is one of the key factors supplementing the growth of the segment. In addition, introduction of technologically advanced products such as Aspiration biopsy syringe gun by INRAD Inc. is supporting the growth of the segment.

Moreover, burgeoning demand for vacuum-assisted devices is influencing the biopsy devices market positively. These devices are manual, semi-automatic, and automatic with a spring-loaded mechanism for minimally invasive insertion to obtain samples for laboratory testing. Such devices demonstrate high efficiency and precision in the withdrawal of large volumes and excellent quality tissue samples with minimal number of passes through the skin.

Continual research and development in the field of medical devices has led to the introduction of various novel equipment and systems in the market, such as medical robotic systems. Robotic guidance systems offer multiple benefits in a procedure such as increasing the total number of surgeries performed by a surgeon and reducing patient stay in the hospital. These systems are used to reduce the total procedural duration to ensure minimal patient discomfort.

Furthermore, in order to minimize cross-contamination incidence rates, healthcare professionals and patients are preferring disposable needles to reusable ones. Rising concerns regarding safety and cross-contamination and introduction of new disposable biopsy needles such as TruGuide (coaxial needle), Biopsy-Cut (core needle), and Ostycut (bone needle) are estimated to augment the market for disposable biopsy needles.

Regional Insights

North America was the leading revenue contributor to the market. Due to established market players domiciled in the region, it will continue to account for a substantial share in the market throughout the forecast period. High market penetration rates of technologically advanced devices such as vacuum-assisted biopsy systems and rapidly growing demand for disposable devices are expected to augur well for the regional market.

The number of biopsies done in the U.S. is the highest. The U.S. FDA has a less stringent regulatory approval process for medical devices since they are considered at moderate risk. There are several government health initiatives aimed at encouraging individuals to undertake regular cancer screening.

Asia Pacific is a promising destination for biopsy device manufacturers. Rapidly improving healthcare infrastructure in emerging Asia Pacific countries, coupled with the presence of high unmet patient needs, and increasing incidence of cancer is anticipated to stimulate the growth of the regional market. According to the World Health Organization (WHO), the number of cancer deaths annually in Asia may reach 6.4 million by 2030, from 4 million in 2007.

Moreover, a research study published in the British Medical Journal stated that Asia has the largest patient population for stomach and liver cancers and the region is likely to witness 58.0% of all cancer cases globally by 2020 and 65.0% by 2050.

High prices of these devices are projected to act as a restraining factor for the market. Furthermore, reforms introduced in India and China are poised to increase the purchasing power of healthcare establishments, thereby, escalating the growth of the market.

Biopsy Devices Market Share Insights

Some of the key players in the market are Inard Inc.; Carefusion Corporation; Devicor Medical Products, Inc.; DTR Medical; Hologic Inc.; C.R. Bard Inc. and Cardinal Health Inc. These companies are involved in developing and adding technologically advanced and cost-effective instruments to their product portfolio.

For instance, in May 2014, Devicor Medical Products Inc. completed the acquisition of HydroMARK breast biopsy marker and its related assets from Biopsy Sciences, LLC. Such collaborations and partnerships are estimated to provide an upthrust to the market in the near future.

Report Scope

Segments Covered in the Report

This report forecasts revenue growth at global, regional, & country levels and provides an analysis of industry trends in each of the sub-segments from 2012 to 2020. For the purpose of this report, Grand View Research has segmented the global biopsy devices market report on the basis of types of products and region:

• Product Outlook (Revenue, USD Million, 2012 - 2020)

  • Needle-based Biopsy Guns

    • Vacuum-assisted Biopsy (VAB) Devices

    • Fine Needle Aspiration Biopsy (FNAB) Devices

    • Core Needle Biopsy (CNB) devices

  • Biopsy Guidance Systems

    • Manual

    • Robotic

  • Biopsy Needles

    • Disposable

    • Reusable

  • Biopsy Forceps

    • General Biopsy Forceps

    • Hot Biopsy Forceps

  • Others

    • Brushes

    • Curettes

    • Punches

• Regional Outlook (Revenue, USD Million, 2012 - 2020)

  • North America

  • Europe

  • Asia Pacific

  • Latin America

  • Middle East & Africa